Two months after receiving Orphan Drug Designation from the U.S. Food and Drug Administration (FDA), Orion Pharma’s investigational drug ODM-212 has received the same benefit from the European Commission. This significant development means the treatment will receive significant incentives on both sides of the Atlantic, offering real hope for its promising new approach to treating the rare asbestos-related disease.
Mesothelioma Drug ODM-212 Targets Pathway Driving Uncontrolled Tumor Growth
ODM-212 addresses mesothelioma through a fundamentally different mechanism from existing therapies. It targets a biological system called the Hippo signaling pathway, which regulates cell growth and malfunctions in mesothelioma. When this happens, it leads to uncontrolled tumor growth and dangerous resistance to cancer therapies. ODM-212 works by blocking mechanisms needed for mesothelioma tumor proliferation.
Taken orally, the small-molecule pan-TEAD inhibitor is being tested in a global Phase 2 clinical study for use in malignant pleural mesothelioma, epithelioid hemangioendothelioma, and other solid tumors impacted by Hippo pathway dysfunction. The trial is being conducted at leading cancer treatment centers in the United States and Europe. Participants are patients who’ve progressed after receiving standard treatments and who have no further treatment options.
Orphan Drug Designation Gives Mesothelioma Treatment Significant Incentives
The FDA’s Orphan Drug Designation granted in April 2026 provides Orion Pharma with special tax credits, user fee exemptions, and eligibility for seven-year market exclusivity for its mesothelioma treatment in the United States. The European Commission’s designation announced this week was based on the recommendation of the European Medicines Agency’s Committee for Orphan Medicinal Products. It adds protocol assistance, fee reductions for regulatory activities, and eligibility for 10 years of market exclusivity if it is approved.
Both designations are specifically for drugs that may offer significant benefit for patients with rare diseases that, like mesothelioma, have no satisfactory existing treatment. The FDA grants Orphan Drug Designation for conditions affecting fewer than 200,000 Americans annually, while the European Commission requires that no more than 5 in 10,000 EU citizens are diagnosed annually.
“The Orphan Designation for ODM-212 is an important milestone for Orion Pharma. It highlights the need for new treatments in mesothelioma and reinforces our commitment to developing innovative therapies for patients with rare cancers,” said Dr. Praveen Aanur, Chief Medical Officer of Oncology Therapy Area at Orion Pharma. For mesothelioma patients who have exhausted standard treatment options, ODM-212’s dual orphan designation represents meaningful progress toward a new approach for a disease that has seen far too few treatment advances.
If you or someone you love has been diagnosed with mesothelioma, the Patient Advocates at Mesothelioma.net are here to help. Contact us today at 1-800-692-8608 to learn more.
